



## Abstract summaries for ACR

Discover some of the scientific data we are presenting this year at the American College of Rheumatology (ACR) Virtual Meeting 2020. Please note that abstract summaries only contain information from the full scientific abstract and selected supporting references. These abstracts have been adapted into plain language summaries to help translate complex data into digestible information. The results of these studies may not reflect those of other studies. Summaries are not intended to provide medical advice nor intended for promotional use.



The image shows a screenshot of a Novartis plain language media summary. The document is titled "Plain Language Media Summary" and features the Novartis logo at the top. The main heading is "Secukinumab effect on the severity of ankylosing spondylitis". Below the heading, the full abstract title is provided: "Subcutaneous secukinumab for the treatment of ankylosing spondylitis: End-of-study results". The authors are listed as Marzo-Ortega H, Mikolajczyk S, et al., and the date is November 2020. A disclaimer at the bottom states: "Please note that this summary only contains information from the full abstract and selected supporting references. The results of this study are not intended to provide medical advice or to be used for promotional purposes."

axSpA



nr-axSpA AS

## Secukinumab effect on the severity of ankylosing spondylitis after 5 years

A simplified overview of the abstract presented November 6, 2020.

[Open summary \(PDF 0.1 MB\)](#)



Plain Language Media Summary

**Secukinumab as a treatment for psoriatic arthritis predominantly affecting the back and neck**

Full abstract title: Secukinumab improves clinical and patient-reported outcomes in patients with psoriatic arthritis predominantly affecting the back and neck (axial joints) in the MAXIMISE trial

Abstract authors: Baraliakos X, Gossec L, et al.  
Date: November 2020

Please note that this summary only contains the key findings and selected supporting references. This summary is not intended to provide a full overview of the abstract.

- pain in the joints and back
- fatigue
- stiffness in the morning
- impaired physical function affecting work and other activities
- problems with self-care
- feelings of anxiety/depression

## Secukinumab as a treatment for psoriatic arthritis predominantly affecting the joints of the back and neck (axial joints)

A simplified overview of the abstract presented November 6, 2020.




[Open summary \(PDF 0.1 MB\)](#)

Plain Language Media Summary

**Using sensitive ultrasound imaging to understand speed of secukinumab response in psoriatic arthritis**

Full abstract title: Secukinumab improves clinical and patient-reported outcomes in patients with psoriatic arthritis predominantly affecting the back and neck (axial joints) in the MAXIMISE trial

Abstract authors: D'Agostino MA, et al.  
Date: November 2020

Metric	Secukinumab*	Placebo
ACR20	68%	34%
ACR50	46%	9%

## Using sensitive ultrasound imaging to understand speed of secukinumab response in psoriatic arthritis

A simplified overview of the abstract presented November 8, 2020.

[Open summary \(PDF 0.1 MB\)](#)


Plain Language Media Summary

## Using machine learning to predict likelihood of achieving relief from psoriatic arthritis


**Full abstract title: Machine learning radiographic damage and long-term outcomes in patients with psoriatic arthritis**

Abstract authors: Mease PJ, van der Heijde D, et al.  
Date: November 2020




*Please note that this summary only covers selected supporting references. The full summary is not intended to provide medical advice.*



Machine learning was used to look back at data from two clinical trials: **FUTURE 1 and FUTURE 5**



**1,554 patients\* with PsA**

	<b>STEP 1</b>	<b>STEP 2</b>	<b>STEP 3</b>
	Assessed how many patients had joint damage on an X-ray at the start and whether there was a relationship between this damage and how much joint swelling and tenderness patients were experiencing		The effect of secukinumab treatment on these symptoms was then studied
			Machine learning looked for a relationship between patients' response to secukinumab treatment and the amount of joint damage at the start of the study

\*Patients receiving secukinumab 75 mg, 150 mg or 300 mg were included in this analysis

## Using machine learning to predict likelihood of achieving relief from psoriatic arthritis

A simplified overview of the abstract presented November 9, 2020.

[Open summary \(PDF 0.1 MB\)](#)

**Source URL:** <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr>

### List of links present in page

1. <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr>
2. [https://prod1.novartis.com/sites/novartis\\_com/files/secukinumab-effect-on-severity-of-ankylosing-spondylitis.pdf](https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-on-severity-of-ankylosing-spondylitis.pdf)
3. [https://prod1.novartis.com/sites/novartis\\_com/files/secukinumab-treatment-for-psoriatic-arthritis-affecting-joints-of-back-neck.pdf](https://prod1.novartis.com/sites/novartis_com/files/secukinumab-treatment-for-psoriatic-arthritis-affecting-joints-of-back-neck.pdf)
4. [https://prod1.novartis.com/sites/novartis\\_com/files/using-sensitive-ultrasound-imaging-understand-speed-of-secukinumab-response-psoriatic-arthritis.pdf](https://prod1.novartis.com/sites/novartis_com/files/using-sensitive-ultrasound-imaging-understand-speed-of-secukinumab-response-psoriatic-arthritis.pdf)
5. [https://prod1.novartis.com/sites/novartis\\_com/files/machine-learning-to-predict-likelihood-of-achieving-relief-from-psoriatic-arthritis.pdf](https://prod1.novartis.com/sites/novartis_com/files/machine-learning-to-predict-likelihood-of-achieving-relief-from-psoriatic-arthritis.pdf)